1 / 68

MUDr. Monika Laššánová

PHLEBOTHROMBOSIS. MUDr. Monika Laššánová. THROMBOSIS. = INTRAVITAL COAGULATION OF BLOOD IN VESSELS OR HEART Incidence of venosus thromboembolism – 0,1% 0,01% among persons cca. 20 years old 1,0% among persons cca. 60 years old.

chandler-torres
Download Presentation

MUDr. Monika Laššánová

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHLEBOTHROMBOSIS MUDr. Monika Laššánová

  2. THROMBOSIS = INTRAVITAL COAGULATION OF BLOOD IN VESSELS OR HEART • Incidenceofvenosusthromboembolism– 0,1% • 0,01% amongpersons cca. 20 yearsold • 1,0% amongpersons cca. 60 yearsold

  3. Patogenesisoftrombosis=(1856) – Wirchow´strias activation of COAGULATION =  activity TXA2,  activity anticoagulant sys. (AT III),  levels or activation of coagulation f. ... slowing down of BLOOD FLOW = stasis, travelling with airplain, right heart failure, paraplegia, immobilisation, gravidity, varixes, operations, fractures ... deffect of VESSEL WALL – by damage of endothel  production PGI2 => proaggregatory activity = neo, infusions, operations... Most important factors

  4. Arterial trombi = white • Trombocytes • Tight adherence => obturation = periferal ischemia • Prevention = antiaggregants • Venal trombi = red • Fibrinal tail • No adherence => migrates = embolisation • Prevention and treatment = anticoagulants • Recent trombi • Are removed (trombolysis) = fibrinolytics

  5. Clinicalconditionscausingthrombosis arterial: • atherosclerosis • smoking • hypertension • diabetes mellitus •  LDL • TAG • possitive family history • deffect of left • oestrogens • polyglobulia … venosus: • general surgery • orthopedical surgery • trauma, malignities, sepsa • immobilisation • congesstive  deffects • nefrotic syndrome • obesity • varixes • postphlebitic syndrome • oestrogens • gravidity

  6. Different! thrombophlebitis phlebothrombosis

  7. THROMBOPHLEBITIS • primarily with mechanic, microbial or chemical irritation inflammation of vessel wallsecondarily can occur thrombosis – forming of grey thrombus with many fibroblasts  firmly adhering to vessel wall, connective tissue is organising embolisation occaisionally • clinically:local syndrome = inflammated firm superficial vein can be palpated, skin above is red, warm, significant pain and sensitivity, no oedema, no general signs or only subfebrility • complications: early – spreading of inflammation to deep venosus sys., late – sec. chronic venosus disease = postphlebitic syndrome

  8. DeepVenosusThrombosis= Phlebothrombosis + its most dangerous complication = pulmonary embolus (PE) – belongs after ICHD and hypertension among the most often KVS diseases of hospitalised persons • PE - 10% of autopsial material • 85% is caused PE by deep venosus thrombosis

  9. PHLEBOTHROMBOSIS (PT) • deep veins of lower extremities • primarily develops obturation of vein with thrombus and only secondarily develops small inflammatory reaction • released thrombus = embolus • clinically: often asymptomatic – or little symptoms = dg. only 30-50% • oedema – is assymetric = difference more than 2 cm • pain – spontanneous, at palpation, compressive – mainly at hanging down the limb, idle spasms, feeling of strain • erythematic - pale - cyanotic – symptom of block of blood flow from the limb • formed collaterals – as compensatory mechanism, after several days of obturation • systemic symptoms – a little specific

  10. Clinicalsymptoms Lowerlimb: • pain • oedema( 1,5 cm) • posit. palp. manoeuvre(Homans, Lőwenberg,...) • enlargedsuperficialcollaterals • changeof skin collour and temperature

  11. Complicationsof PT • EMBOLUS is by blood flow carried reliesed trombus – mainly to pulmonary artery pulmonary embolism • Repeated embolisation (successive) =>chronic pulmonary hypertension => cor pulmonale chronicum • Chronic venous insufficiency

  12. Goalofthetreatmentof PT • acute condition • save patient´s life • inicialise and speed-up thrombembolic resolution • accelerate symptom regression • prevention of recurrency • reduce mortality

  13. nonpharmacologic limb elevation (15-20º) soonmobilisationaftersurgery regularexcercisewithlegs in bed elastic, specialtights walking pharmacologic lowdosesofheparin(5000 IU) (beforeoperation, duringpostoperationperiodat risk patients) Preventionof PT

  14. Situation:You are a generalpractitioner. Followingpatientcomes to you:

  15. Mr. Novák iscomplaining, that , sinceplasterwasputdownfromhisright leg beforeoneweek, successivelyhisright leg gotswollen, hefeelspainatwalking and last 2 daysstartedwithdifficulty to breath. Hefeelsstitching on therightsideofchestgetting more emphasizedatinspiration. • Atphysicalexaminationobservedtachypnoe, accentationof 2nd heartsoundabovepulmonaryartery, attenuatedbreathingatbasalrightside, right leg swollenassymetrically, positiveHomans and Löwenberg. • Atlaboratoryexaminationhypoxia in arterialblood. • Workoutpharmacotherapeuticplan.

  16. Antithrombotics • antiaggregants(antiplateletdrugs) = blockFORMATIONofthrombus • anticoagulants= blockGROWTH ofthrombus • thrombolytics(fibrinolytics) = DISSOLUTIONofalreadyformedthrombus

  17. Anticoagulants • DRUGS ARTIFICIALLY INDUCING “DISTURBANCES“ OF BLOOD COAGULATION • GOAL: TO PREVENT THROMBOSIS OR TO STOP PROGRESSION OF ALREADY FORMED THROMBUS

  18. HEPARIN • UNDIRECT INHIBITOR OF THROMBIN • SUBSTANCE OWN TO BODY (MAST CELLS), USED FROM 1916 • MW = 3 - 30 000 D (15 000 D) • produced from intestinal mucosa of porcine or cattle lungs => qualified in IU • heterogenous anion mucopolysacharid – the strongest organic acid in organism • ACTIVITY IS DEPENDENT FROM THE PRESENCE OF A N T I T H R O M B I N III.

  19. Mechanismofactionofheparin - + 1000x H inactivates already activovated coagulation factors IIA, IXA, XA, XIA

  20. Effectsofheparin • anticoagulant – IIA = inactivation of thrombin (bleeding manifestation) • antithrombotic – XA = inhibition of thrombin formation • inhibition of platelet function -  adhesivity and aggregation • stimulation of fibrinolysis • releasing of lipoproteinic lipase  clearing of lipemic plasma anticoagulatef. anti - IIa : anti -Xaantithromboticef. 1 : 1

  21. Advantagesofheparin • acts very fast or immediately, but shortly • has massive effect • it has effective antidote, 1 ml protamine binds 100 IU H

  22. Disadvantagesofheparin • only injection (i.v., s.c.), • i.m. – no, irregular absorption and haematoma • T1/2 is variable, prolonged with  dose, 3 times per day s.c. • unpredictable anticoagulant effect – wide variability (for different binding to proteins and unpredictable BD at s.c.) • possibility of disease reactivation after stopping administration (rebound efect) • control:APTT (reflexts effect to thrombin) – extension to 1,5-2,5 x of norm

  23. Indicationsofheparin • Th. of deep vein thrombosis and pulmonary embolia • Prophylaxis of vein thrombosis • Prevention of coronary thrombosis (AP, IM) • AIM without TL • Atrium fibrillation • Obturation of peripheral arteries • Hemodialysis, DIC

  24. ADR ofheparin • Bleeding • H. inducedthrombocythopenia(HIT) – lessserious, earlyf.; more seriousf. after5 and  days occurenceofthrombosis • Allergy • Reversiblealopecia • Osteoporosisatlong-termuse

  25. LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) • INDIRECT INHIBITORS OF THROMBIN • small molecules, MR  5 000 D • INHIBIT MORE ANTI-XA • PRODUCED BY CHEMIC OR ENZYMATIC DEPOLARISATION OF H • ACTIVITA DEPENDS ON THE PRESENCE OF A N T I T H R O M B I N   III

  26. Methodsof LMWH production • depolymerisation • kyselinou dusitou • hydrolysis • heparinisation • irradiation • isolationoflow-molecularfraction • jellyfiltration • ultrafiltration • alcoholextraction

  27. Mechanismof LMWH action anticoagulat. ef.anti - IIa : anti -Xaantithromboticef. 1 : 2 - 4

  28. FONDAPARINUX • INDIRECT INHIBITOR OF THROMBIN • SYNTHETIC PENTASACHARID SPECIFICALLY INHIBITING FACTOR XA • MR = 1 700 D • activity depends on the presence of A N T I T H R O M B I N   III • 300X  ability to inactivate f. XA

  29. MA offondaparinux

  30. Advantagesoffondaparinux • doesn´t have long chain needed to binding to f. IIA  doesn´t inhibit thrombin of bleeding complications also than LMWH • administered s.c. • long duration of action • highly predictable effect • doesn´t influence aggregation of platelets  doesn´t induce thrombocythopenia • disadvantage = price

  31. HIRUDIN, BIVALIRUDIN • DIRECT INHIBITOR OF THROMBIN •  SPECIFICALLY IRREVERSIBLYINACTIVATES THROMBINWITHOUT NEED OF AT III PRESENCE • IS NATURAL INHIBITOR OF BLOOD COAGULATION GAINED FROM LEECH (HIRUDO MEDICINALIS) • PRODUCED BY DNA RECOMBINANT TECHNOLOGY

  32. MA HIRUDINIS BIND TO THROMBIN AND irreversibly FORMS INACTIVE COMPLEX BIVALIRUDIN-synthetic fragment of thrombin - reversible inhibition of thrombin - duration of action cca 25 min.

  33. Advantagesofhirudin • doesn´t bind to plasma proteins predictable anticoagulant effect • indicated for patients with thrombocythopenia after heparin with need to th. • inactivates not binded, but also thrombin binded to fibrin in thrombus anticoagulant effectivity • inhibits formation of fibrin • inhibits activation of thrombocyts = antiaggregatory effect • prevents activation of f. V, VIII, XI and XIII • peg-hirudin – 1 times per day, s.c.

  34. COUMARINS • I N D I R E C T p.o.ANTICOAGULANTS = ANTAGONISTS OF VITAMIN K  factors II., VII., IX., X. DOESN´T ACT ANTICOAGULATORY IN VITRO • DISCOVERED ACCIDENTALLY – LIVESTOCK ATE FERMENTED SHAMROCK– SUBSTANCES IN IT CAUSED DEFICIENCY OF PROTHROMBIN– ANIMALS WERE BLEEDING • Otheruse– poisonforgnawer

  35. MA warfarin • inhibition of epoxidreductase, no formation of vitamin K active form  no activation of -carboxylase and no carboxylation of -glutamin residuums of factors II., VII., IX., X. + inhibition of protein C and S carboxylation  • coumarins antagonise liver synthesis of f. II, VII, IX and X => • formed are incomplete, unfunctional molecules, which don´t cause coagulation

  36. Pharmacokineticofwarfarin • 100% BA, 99% binding to plasma proteins  small distribution volume + long plasma half-life=>many interactions • EFFECT STARTS WITH LATENCY 12-24 HOURS, MAXIMAL EFFECT AFTER 2-3 days • AFTER SECESSION effect REMAINS 4-5 days

  37. DISADVANTAGES ofwarfarin • starting and remaining of effect after secession withlatency (2-3days) • no therapy of a c u t e conditions => prophylaxis • Control of therapy and dosage according to INR (2,0-4,5– according to indication) • Controls of INR v stabilized condition each 3-4 weeks

  38. INR • International normalised ratio patient´s Quick time • INR = Quick time of standard • Prophylaxis of thrombosis INR = 2,0 – 2,5 • Therapy of thrombosis INR = 2,0 – 3,0 • At pat. with antiphospholipid sy. • INR = 3,0 – 4,5

  39. Interactions of Warfarin • pharmacokinetic • high binding to plasma proteins • metabolised with CYP 450 • pharmacodynamic - groceries with high amount of vitamin K, can reduce effect - antibiotics that suppress bacterias in GIT that produce vitamin K (3rd generation of cephalosporins), can increase effect

More Related